Laterza v. New York State Racing & Wagering BoardLaterza v. New York State Racing & Wagering Board
Petitioner, licensed by respondent to own and train race horses since 1973, was the trainer of record for a horse named “Lemon Pepper,” which competed in the ninth race at Yonkers Raceway on April 27, 2007, finishing in third place. Acting on a tip from a police informant, respondent‘s director of investigations requested the presiding judge at Yonkers Raceway to order that post-race double blood and urine samples be taken from Lemon Pepper and tested for the presence of recombinant human erythropoietin (rhEPO) or Darbepoietin-alfa (DPO) (hereinafter collectively referred to as rhEPO/DPO). These chemically engineered drugs—which mimic the naturally produced human EPO hormone that has the ability to increase red-blood cell production and its consequent increased oxygenation—are not specifically permitted to be administered to horses (see
George Maylin, professor of toxicology at the New York State College of Veterinary Medicine at Cornell University and Director of the New York State Equine Drug Testing and Research Program, conducted an ELISA1 antibody screening test on the blood sample. The test revealed that the blood sample had an immuno response to an EPO antibody, indicating that rhEPO/DPO may have been present, but he did not have the means to confirm the actual presence of this restricted substance. To confirm the actual presence of rhEPO/DPO, Maylin was authorized by respondent to send a separate sample to Cornelius Uboh, Bureau Director of the Pennsylvania Equine Toxicology and Research Laboratory, for testing.2 Uboh, employing a sequence of well-established scientific tests that he and his research colleagues had devised to recover and identify rhEPO/DPO from an equine blood sample, confirmed that the blood sample contained that substance. Based upon Uboh‘s confirmatory test, Maylin advised respondent of the positive result.
In October 2007, the presiding judge at Yonkers Raceway concluded that petitioner had violated
To greatly simplify, Uboh testified that, using commercially purchased antibodies as magnets to attract the rhEPO/DPO and separate it from horse plasma (immuno affinity separation), he washed off and recovered the substance itself (from the antibodies) and analyzed it using a mass spectrometer (LC-MS/MS instrument), which broke the substance down into peptides at specific points using enzymes (tryptic digestion); he then confirmed that the peptides were the prohibited substance using an internationally recognized database (to identify peptides that do not occur naturally in horses). Maylin testified that all of these techniques were scientifically accepted, that immuno affinity separation was “widely used in protein chemistry,” that tryptic digestion was a process “used for 35 years,” and that the mass spectrometer was “widely used” in the study of proteins, but very expensive and rare.3 Uboh testified that it was the use of this mass spectrometer instrument for this purpose that was a first. Further, it was established at the hearing that Uboh‘s technique—developed after four years of collaborative research—had been published in a peer review scientific journal in June 2007, shortly after this race, and further refined in an April 2008 article published just before his testimony.4
Under the circumstances here, we are not persuaded that the
Turning to our review of the determination, we find that respondent submitted substantial evidence that the horse‘s blood tested positive for rhEPO/DPO. However, the record fails to establish, as required, that it was administered within the seven-day proscribed period (see
Petitioner‘s remaining claims need not be addressed in light of the foregoing.
Peters, J.P., Lahtinen, Kane and Malone Jr., JJ., concur.
Adjudged that the determination is annulled, without costs, and petition granted.